drugset / Trial / NCT05673928
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Phase 2
Recruiting
30 enrolled
M.D. Anderson Cancer Center
Genentech, Inc. · collabSeagen Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Timeline
- Start
- 2023-05-16
- Primary completion
- 2027-03-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab emtansine | Other / unclassified | — | Intravenous |
| Subject | Tucatinib | Small molecule | — | Oral |